eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2020
vol. 16
 
Share:
Share:
more
 
 
abstract:
Original paper

Response to antiplatelet therapy in patients undergoing invasive treatment due to acute coronary syndrome complicated by cardiogenic shock

Wiktor Kuliczkowski
1
,
Magdalena Cielecka-Prynda
1
,
Bożena Karolko
1
,
Konrad Kaaz
1
,
Barbara Adamik
2
,
Dawid Bednarczyk
1
,
Małgorzata Kobusiak-Prokopowicz
1
,
Andrzej Mysiak
1

1.
Department and Clinic of Cardiology, Wroclaw Medical University, Wroclaw, Poland
2.
Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland
Adv Interv Cardiol 2020; 16, 4 (62): 418–421
Online publish date: 2020/12/29
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
There are limited data on platelet reactivity and response to antiplatelet drugs in patients with cardiogenic shock. Aim: To assess platelet reactivity on dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor, a novel potent P2Y12 receptor inhibitor, in patients with cardiogenic shock in the course of acute coronary syndrome (ACS) who received invasive treatment.

Material and methods
We enrolled 12 consecutive patients with ACS complicated by cardiogenic shock. To assess response to antiplatelet therapy during cardiogenic shock, only patients with symptoms persisting for at least 3 days and who completed a 5-day follow-up were included in the study. Patients received a loading dose of ASA (300 mg) and ticagrelor (180 mg), followed by a maintenance dose (ASA, 1 × 75 mg; ticagrelor, 2 × 90 mg). Blood samples for platelet function tests were collected. Platelet aggregation was assessed with a Multiplate whole-blood impedance aggregometer. Arachidonic acid (AA), adenosine diphosphate (ADP), and thrombin receptor-activating peptide (TRAP) were used as aggregation agonists.

Results
Response to antiplatelet therapy assessed by aggregometry showed numerically higher on-ASA platelet reactivity on day one and statistically significant higher on-ticagrelor platelet reactivity on day one in comparison with following days. There were 2 patients with high on ASA platelet reactivity and 3 with high on ticagrelor platelet reactivity, but only on the day one.

Conclusions
Some patients with cardiogenic shock in the course of ACS treated invasively show a lower response to ASA and ticagrelor only on the first day after invasive treatment, with a good response on subsequent days.

keywords:

antiplatelet therapy, cardiogenic shock, myocardial infarction, ticagrelor

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe